Hwang Kuk Hyoun

Chief Executive Officer, Director, 10% OwnerBellevue Life Sciences Acquisition Corp. (BLAC) · full profile →Form 4 · filed Feb 16, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
11
8 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 14, 2023Other(J)20K$01.6M
Feb 14, 2023Other(J)20K$01.7M
Feb 14, 2023Other(J)20K$01.7M
Feb 14, 2023Other(J)20K$01.7M
Feb 14, 2023Grant(A)430K$10.00$4.3M1.8M
Feb 14, 2023Other(J)20K$01.6M
Feb 14, 2023Other(J)225K$01.4M
Feb 14, 2023Other(J)30K$01.4M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 14, 2023Buy(P)430K$10.00$4.3M430K
Feb 14, 2023Other(J)20K$0390K
Feb 14, 2023Other(J)20K$0410K

Transaction Codes

J
Other acquisition / disposition
A
Grant / award
P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-23-005295) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Ask your agent about BLAC insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0000899243-23-005295"
Ask your agent
Use Arkolith to summarize insider buying and selling at Bellevue Life Sciences Acquisition Corp.
over the last 90 days and cite the filings.